However, recent studies confirmed the potential for IFNs to enhance expression of host angiotensin-converting enzyme 2 (ACE2), suggesting that IFN treatment or natural co-infection may aggravate COVID-19 by up-regulating this critical virus entry receptor [52,53]. This evidence concerns the gene ACE2 and COVID-19.